ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

ImageneBio IncNASDAQ: IMA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$174K, compared with -$3.72M a year earlier. Trailing-twelve-month gross profit was -$780K.

Context

  • Gross profit amounted to 29.1% of revenue in FY2025, down 70.9 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$174K or moves back toward the trailing-twelve-month quarterly average of -$195K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$174K+69.0% QoQ
Last fiscal yearDec 2025
-$233K-106.7% YoY
LTMMar 2026
-$780K+95.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+95.3%——
1 year-106.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(233K) USD
Year-over-year change
-106.7%

Gross Profit vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +95.0% is the 2nd highest of 6, against a peer median of -99.8%.
IMA Competitors
Gross Profit for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$98.33M USD+52.1%+17.0%98.7%
OVIDOvid Therapeutics Inc.LTM Mar 2026$7.09M USD+1193.2%+66.6%99.5%
CNTBConnect Biopharma Holdings LimitedFY2025$64K USD-99.8%—100.0%
KLRSKalaris Therapeutics IncLTM Mar 2026-$20K USD———
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.17K USD———
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$666K USD———
IMAImageneBio IncLTM Mar 2026-$780K USD+95.0%——
STTKShattuck Labs, Inc.LTM Mar 2026-$820K USD-146.7%—82.0%
IFRXInflaRx N.V.LTM Mar 2026-€7.23M EUR-142.9%—24646.3%
Peer median (excluding IMA) —-99.8%+41.8%99.5%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.99M15.62M9.16M3.5M800K
Cost of Revenue47.11M64.32M1.02M1.53M1.03M
Gross Profit(16.12M)(48.7M)8.14M3.5M(233K)
Gross Margin-52.0%-311.8%88.9%100.0%-29.1%
Research & Development47.11M64.32M59.65M32.11M28.53M
Selling, General & Admin18.02M22.2M24.93M8.39M20.73M
Operating Expenses18.02M22.2M83.56M40.5M48.22M
Depreciation & Amortization544K751K1.02M1.53M1.03M
EBITDA(33.57M)(68.01M)(67.31M)(35.03M)(44.67M)
EBITDA Margin-108.3%-435.5%-734.8%-1000.8%-5583.3%
Operating Income(34.14M)(70.9M)(75.42M)(37M)(48.45M)
Operating Margin-110.2%-454.0%-823.3%-1057.1%-6056.4%
Interest Income23K2.15M7.11M7.37M2.04M
Interest Expense00000
Other Income / Expenses23K2.14M7.09M445K2.75M
Income Before Tax(34.12M)(68.77M)(68.33M)(36.56M)(45.7M)
Pre-Tax Margin-110.1%-440.3%-745.9%-1044.4%-5712.4%
Income Tax Expense00(162K)13K(350K)
Net Income(34.12M)(68.77M)(68.17M)(36.57M)(45.35M)
Net Margin-110.1%-440.3%-744.2%-1044.8%-5668.6%
EPS (Basic)(0.95)(1.90)(1.63)(1.02)(10.76)
EPS (Diluted)(0.95)(1.90)(1.63)(1.02)(10.76)
Weighted Avg Shares35.98M36.19M41.74M48.26M4.87M
Weighted Avg Shares (Diluted)35.98M36.19M41.74M48.26M4.87M

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.